Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Guangzhou Lupeng Pharmaceutical Company LTD.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
66High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06665217CT.gov G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | — | Not Yet Recruiting | — | — | — |
NCT07126236CT.gov Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma | — | Recruiting | — | — | — |
NCT06803693CT.gov Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | — | Recruiting | — | — | — |
NCT06758037CT.gov Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy | — | Recruiting | — | — | — |
NCT06441097CT.gov Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06748521CT.gov Dynamic CtDNA-guided Targeted Therapy in DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06651853CT.gov Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL | — | Recruiting | — | — | — |
NCT06516978CT.gov A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCL | — | Not Yet Recruiting | — | — | — |
NCT06664411CT.gov Pola-ZR2P in Previously Untreated DLBCL | — | Recruiting | — | — | — |
NCT06503263CT.gov Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCL | — | Recruiting | — | — | — |
Show 55 more trialsShow fewer
NCT06220032CT.gov Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma | — | Recruiting | — | — | — |
NCT06508658CT.gov A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT06522555CT.gov The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma | — | Recruiting | — | — | — |
NCT06015880CT.gov Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT06521255CT.gov Evaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | Recruiting | — | — | — |
NCT06151080CT.gov Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | — | Recruiting | — | — | — |
NCT06176729CT.gov Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients | — | Recruiting | — | — | — |
NCT05626322CT.gov Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | — | Terminated | — | — | — |
NCT05883709CT.gov A Real-world Study of Tafasitamab in Combination With Lenalidomide in Patients withR/R DLBCL | — | Unknown | — | — | — |
NCT05923879CT.gov Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT05821088CT.gov Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | — | Suspended | — | — | — |
NCT05784987CT.gov R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | — | Unknown | — | — | — |
NCT05660967CT.gov Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT05429268CT.gov Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND) | — | Active Not Recruiting | — | — | — |
NCT05575973CT.gov Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | — | Unknown | — | — | — |
NCT05498636CT.gov SPEL as Introductive Treatment Following Immune-chemotherapy as Consolidated Therapy for R/R DLBCL With p53 and/or c-Myc Expression | — | Unknown | — | — | — |
NCT05222555CT.gov Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Patients | — | Active Not Recruiting | — | — | — |
NCT05428670CT.gov The Efficacy and Safety of ZR2 Versus R-CHOP-like Regimen for Elderly Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma. | — | Unknown | — | — | — |
NCT05351346CT.gov Genotype-guided Treatment in DLBCL | — | Unknown | — | — | — |
NCT05186558CT.gov Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL | — | Unknown | — | — | — |
NCT05328102CT.gov Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) | — | Terminated | — | — | — |
NCT05265975CT.gov A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL | — | Terminated | — | — | — |
NCT04978584CT.gov Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study | — | Active Not Recruiting | — | — | — |
NCT05179733CT.gov The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | — | Unknown | — | — | — |
NCT04974216CT.gov Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older | — | Active Not Recruiting | — | — | — |
NCT05290090CT.gov ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | — | Unknown | — | — | — |
NCT05552937CT.gov Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Recruiting | — | — | — |
NCT04739813CT.gov Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT04824092CT.gov Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients | — | Active Not Recruiting | — | — | — |
NCT04842487CT.gov R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study | — | Unknown | — | — | — |
NCT04796857CT.gov Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL | — | Unknown | — | — | — |
NCT04661007CT.gov To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) | — | Active Not Recruiting | — | — | — |
NCT04663347CT.gov Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04446962CT.gov LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) | — | Active Not Recruiting | — | — | — |
NCT04622579CT.gov Lenalidomide Combined With Rituximab as Front-line Therapy for DLBCL Patients Aged Over 80 Years | — | Unknown | — | — | — |
NCT04460248CT.gov Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL) | — | Active Not Recruiting | — | — | — |
NCT04542824CT.gov Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) | — | Active Not Recruiting | — | — | — |
NCT04404283CT.gov Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | — | Active Not Recruiting | — | — | — |
NCT04134936CT.gov Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | — | Completed | — | — | — |
NCT04025593CT.gov Biomarker Guided Treatment in DLBCL | — | Unknown | — | — | — |
NCT03949062CT.gov Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL | — | Unknown | — | — | — |
NCT03223610CT.gov Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | — | Recruiting | — | — | — |
NCT03003520CT.gov A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma | — | Completed | — | — | — |
NCT02281279CT.gov Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma | — | Withdrawn | — | — | — |
NCT02955823CT.gov A Phase II Study of the FIL on Elderly Frail Patients With DLBCL | — | Completed | — | — | — |
NCT02636322CT.gov Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib | — | Completed | — | — | — |
NCT02399085CT.gov Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL | — | Completed | — | — | — |
NCT02086604CT.gov Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma | — | Completed | — | — | — |
NCT01953692CT.gov A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | — | Completed | — | — | — |
NCT01075321CT.gov Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | — | Completed | — | — | — |
NCT02340936CT.gov Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | — | Completed | — | — | — |
NCT01241734CT.gov Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL | — | Completed | — | — | — |
NCT01116154CT.gov Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | — | Terminated | — | — | — |
NCT00968331CT.gov Study of Lenalidomide(Revlimid) Plus Rituximab (Revlirit Regimen) in Elderly Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) | — | Terminated | — | — | — |
NCT00474188CT.gov A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diffuse Large B-Cell Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenalidomide (this asset) | Guangzhou Lupeng Pharmaceutical Company LTD. | P3 | BB · 68 |
| Vincristine Sulfate | National Cancer Institute (NCI) | P2/3 | A |
| Melphalan | Ruijin Hospital | P4 | BBB |
| Axicabtagene Ciloleucel | Ruijin Hospital | P4 | BBB |
| Prednisone | Beth Israel Deaconess Medical Center | P4 | BBB |
| Nivestim | Ruijin Hospital | P3 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P3 | BBB |
| Adriamycin | Beth Israel Deaconess Medical Center | P4 | BBB |
| Cyclophosphamide | Beth Israel Deaconess Medical Center | P4 | BBB |
+42 more in the Diffuse Large B-Cell Lymphoma cohort
Other indications for Lenalidomide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 74 |
| Plasma Cell Neoplasm | — | P3 | BBB · 72 |
| B-Cell Non-Hodgkin Lymphoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenalidomide in Diffuse Large B-Cell Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenalidomide-diffuse-large-b-cell-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →